← Back to Search

Treatment sequences C-B-A-D for Hot Flashes

Phase 1
Waitlist Available
Research Sponsored by Bayer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Females aged 40 to 65 years, inclusive, at signing of informed consent
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 9 hours after last dose
Awards & highlights

Study Summary

This trial is testing a new treatment called elinzanetant for hot flashes, which are intense feelings of heat, sweating, and redness of the skin. The treatment works by blocking a substance

Who is the study for?
This trial is for healthy women experiencing vasomotor symptoms like hot flashes due to hormone imbalance. Participants should be able to complete a driving simulator test and commit to multiple study site visits over approximately 15 weeks.Check my eligibility
What is being tested?
The trial tests elinzanetant's effect on driving ability and brain function in women with hot flashes. It involves comparing two doses of elinzanetant, a sleep aid drug zopiclone, and placebos through four treatment periods using a computer-based driving simulation.See study design
What are the potential side effects?
Elinzanetant may cause drowsiness or tiredness that could affect activities such as driving. Zopiclone is known for treating sleep issues but can also lead to similar side effects like sleepiness.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a woman aged between 40 and 65.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 9 hours after last dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 9 hours after last dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Simulated driving performance as measured by SDLP using CRCDS-MiniSim
Secondary outcome measures
Average Speed and Speed Deviation
CogScreen Symbol Digit Coding Test: Number of Correct responses
CogScreen Symbol Digit Coding Test: Response Accuracy (percentage of correct responses)
+11 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: Treatment sequences D-A-B-CExperimental Treatment4 Interventions
Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).).
Group II: Treatment sequences C-B-A-DExperimental Treatment4 Interventions
Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).
Group III: Treatment sequences B-D-C-AExperimental Treatment4 Interventions
Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).
Group IV: Treatment sequences A-C-D-BExperimental Treatment4 Interventions
Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Elinzanetant (BAY3427080)
2022
Completed Phase 3
~1940
Zopiclone
2011
Completed Phase 4
~1910
Placebo to elinzanetant
2024
Completed Phase 1
~70
Placebo to zopiclone
2024
Completed Phase 1
~70

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

BayerLead Sponsor
2,247 Previous Clinical Trials
25,333,521 Total Patients Enrolled
13 Trials studying Hot Flashes
3,540 Patients Enrolled for Hot Flashes
~43 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top